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An update 
on the management 
of hypertension
This article provides an update on the management of hypertension 
mostly based on the recent clinical guidelines issued by the National 
Institute of Clinical Excellence (NICE).1 Key points being highlighted 
are the importance of assessment of the cardiovascular disease (CVD) 
risk and the fact that beta-blockers (BBs) are no longer considered 
as appropriate first-line agents (in the absence of other indications 
for beta-blockade). The importance of fully involving patients in 
treatment decisions on an on-going basis is also emphasised.
Marise	Gauci	B Pharm (Hons), MSc
Introduction
Hypertension is a major modifiable 
risk factor for cardiovascular disease. Any 
definition of hypertension is arbitrary.2 
Consensus from published guidelines is that 
hypertension is defined as a persistently 
raised blood pressure (BP) of above 
10/90mmHg. 
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Cardiovascular	risk
The co-existence of other modifiable 
risk factors (e.g. elevated cholesterol, 
smoking, diabetes) and non-modifiable 
risk factors (e.g. old age, family history 
of CVD, male gender) has a bearing on 
the management strategy for the patient. 
Health professionals should use a validated 
risk assessment tool, such as that produced 
by the Joint British Societies (JBS), as 
an aid for deciding when treatment is 
necessary. The latest version of the JBS 
chart is available in the British National 
Formulary (BNF).3
Treating hypertension should not be 
viewed in isolation and other interventions, 
such as statins and aspirin, should be 
considered on the basis of a person’s history 
of CVD or an assessment of their CVD risk. 
The NICE appraisal of statins recommends 
their use (i) for adults with clinical 
evidence of CVD (i.e. secondary prevention) 
and, (ii) as part of the management 
strategy for the primary prevention of 
CVD for adults who have a 20% or greater 
10-year risk of developing CVD. Aspirin 
7mg daily is recommended for all people 
with established CVD. Thresholds for using 
low-dose aspirin to prevent cardiovascular 
events in people without existing CVD are 
difficult to define. The British Hypertension 
Society recommends aspirin 7mg daily 
for primary prevention in patients with 
hypertension aged >0 years with BP 
controlled to <10/90mmHg and either 
target organ damage, diabetes mellitus, or 
10-year CVD risk of >20%.6
Treatment	thresholds	and	targets
Thresholds for treatment of raised BP 
consider overall CVD risk, in addition to 
the absolute BP level. Drug therapy should 
be offered to patients with persistently 
high BP of 160/100mmHg or more, and 
patients at raised CVD risk (10-year risk 
of CVD of 20% or more, or existing CVD or 
target organ damage) with persistent BP 
of >10/90mmHg.1 Lower thresholds are 
recommended for patients with diabetes 
(Table 1).7,8
The evidence base on optimal target 
BP for both systolic BP and diastolic 
BP remains incomplete. NICE guidance 
recommends a BP treatment target of 
10/90mmHg for non-diabetic patients.1 
Lower BP targets are recommended for 
those with diabetes (Table 1).7,8 Patients 
who are at the highest baseline risk of CVD 
have the most to gain from lowering of BP.9 
Although it may not be possible to achieve 
target in all patients, any lowering of BP 
is beneficial. The aim is to achieve the 
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largest reduction possible toward the target, 
considering tolerability and concordance for 
each individual patient.10
Lifestyle	interventions
A healthier lifestyle, by lowering BP 
and CVD risk, may reduce, delay or remove 
the need for long-term therapy in some 
patients.9 All guidelines recommend that 
lifestyle interventions should form an 
integral part of the management of high BP 
either alone or in addition to drug therapy.  
Key interventions and the associated	
Thresholds	for	initiating	treatment	(either	systolic	or	diastolic	within	ranges)
Patients	without	diabetes Treat if persistent BP>10-19/90mmHg and 10-year CVD 
risk ≥ 20% or existing CVD or target organ damage
   
 Treat all patients with persistent BP ≥ 160/100mmHg
   
Patients	with Treat if BP ≥ 10-19/80-99mmHg and 10-year CVD risk
type	2	diabetes >20% or concomitant microalbuminuria or proteinuria 
     
 Treat all patients with BP ≥ 160/100mmHg  
    
Patients	with	 Treat if BP ≥ 13/8mmHg 
type	1	diabetes 
 Treat if BP ≥ 130/80mmHg and abnormal albumin 
excretion rate or two or more features of the metabolic 
syndrome      
Targets	for	treatment	(both	systolic	and	diastolic	BP	to	be	achieved)
Patients	without	diabetes ≤ 10/90mmHg     
 
Patients	with < 10/80mmHg or ≤ 13/7mmHg if microalbuminuria 
type	2	diabetes	 or proteinuria present    
  
Patients	with	 < 13/8mmHg or < 130/80mmHg if nephropathy
type	1	diabetes
Table	1:	Thresholds	and	targets	in	the	NICE	hypertension	and	diabetes	guidelines1,7,8
Systolic	and	Diastolic	BP	
reductions	in	trials
Adopt a healthy low calorie diet. -6mmHg
Take aerobic exercise for 30-60 minutes, three to five times each week. 2-3mmHg
Limit alcohol consumption to no more than 21 units/week (men) 
and 1 units/week (women), with  intake spread out over the week. 3-mmHg
Reduce dietary sodium intake to less than 2.g (100mmol) per day. 
This is equivalent to 6g of salt. 2-3mmHg
Avoid excessive consumption of coffee (≥  cups) 
and other caffeine-rich products that can raise BP.
Stop smoking. This has benefits on CVD, if not directly on high blood pressure.
Table	2:	Key	lifestyle	advice	for	patients	and	associated	BP	reductions1,9
changes in BP that have resulted from 
adherence in trials are given in Table 2.1,9 
Lifestyle modifications can be difficult to 
achieve and patients need regular follow-
up and support to maintain changes in the 
long-term.
Drug	treatment	strategy
A range of effective antihypertensive 
drugs from different pharmacological classes 
can be considered for the treatment of 
hypertension. In June 2006, NICE updated 
its guidance on the drug treatment of 
hypertension. Recommendations were made 
following a systematic review of randomised 
controlled trial data which found no 
difference between the classes of drugs with 
regard to the risk of death or myocardial 
infarction. However, BBs were considered 
less effective than comparable drugs in 
reducing the risk of stroke.11 Thiazide 
diuretics and calcium channel blockers 
(CCBs) were considered the most likely 
drugs to confer benefits in cardiovascular 
outcomes, except possibly in younger 
patients. BBs are no longer considered by 
NICE as an appropriate choice for initial 
treatment of hypertension unless there 
are compelling reasons to use them (e.g. 
coronary artery disease).1
Figure 1 depicts an algorithm for the 
drug treatment of patients with newly 
diagnosed hypertension.1 Low-dose thiazide 
diuretics or CCBs are considered by NICE as 
equal first-line choices for patients over  
years of age. As the recommendations do 
not distinguish between the two options, 
prescribers may decide on the basis of 
the patient’s risk of adverse effects, 
patient preference and costs. Angiotensin-
converting enzyme inhibitors (ACEIs) are 
recommended for younger patients. Where 
an ACEI is indicated but not tolerated 
(e.g. because of cough), an angiotensin-II 
receptor blocker (AIIRB) is appropriate. BBs 
are indicated as initial treatment only in 
particular situations namely in patients with 
coronary artery disease, women of child-
bearing potential, patients with evidence 
of increased sympathetic drive, or patients 
with an intolerance or contraindication to 
ACEIs and AIIRBs. NICE recommendations 
for patients already receiving BBs are 
summarised in Panel 1.1
Many patients will require more than 
one drug to achieve BP control. Where 
the first-line drug does not adequately 
control BP, additional drugs should be 
added in a sequential manner according 
to the algorithm. The drug combinations 
recommended are not supported by large 
clinical outcome studies, but is based on 
sound pathophysiological grounds.10  
Treatment of patients with hypertension 
and diabetes was not considered in the 
development of the updated NICE guideline, 
and although not explicitly stated, the 
recommendations do not apply to patients 
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 < years  ≥  years
   or black+ (any age)
Step 1 A‡  C or D  
    
Step 2  A+C or A+D 
    
Step 3  A+C+D  
Step   A+C+D   
  +   
  further diuretic therapy, or α-blocker, or β-blocker
  Consider specialist advice   
   
+of African or Caribbean descent, and not mixed race, Asian or Chinese   
‡ β-blockers are an alternative to A in patients younger than  years if A is not tolerated or is 
contraindicated (including women of childbearing potential)       
A=ACEI  e.g. enalapril -20mg once dly
  lisinopril 10-20mg once dly      
  perindopril -8mg once dly        
or AIIRB e.g. candesartan 8-16mg once dly  
(if intolerant)  eprosartan 600-800mg once dly     
  losartan 0-100mg once dly      
  telmisartan 0-80mg once dly      
  valsartan 80-160mg once dly
  
C=calcium channel blocker e.g. amlodipine -10mg once dly    
D=thiazide-type diuretic e.g. bendroflumethiazide 2.mg once dly
 indapamide 1.mg once dly     
β-blocker e.g. atenolol 0mg once dly
α-blocker e.g. doxazosin -8mg once dly, terazosin 2-10mg once dly  
  
usual maintenance doses; lower dose may be required in elderly and in renal or liver impairment
Figure	1:	NICE	algorithm	for	the	drug	treatment	
	 of	patients	with	newly	diagnosed	hypertension1,3	 	
If BP is controlled, consider long-term management at a routine review. There is no 
absolute need to replace the β-blocker with an alternative agent.   
      
If BP is not controlled, revise treatment according to the treatment algorithm 
(see Figure 1).        
 
When a β-blocker is withdrawn, step the dose down gradually.   
      
Do not withdraw the β-blocker if there is a compelling indication for being treated with 
one, such as symptomatic angina or a previous myocardial infarction.
Panel	1:		NICE	recommendations	for	patients	already	receiving
	 a	regimen	that	includes	a	β-blocker1	
with diabetes. In these patients, a thiazide 
diuretic or an ACEI is an appropriate 
first-line choice, with a combination of 
these two drugs being used should BP 
control not be achieved. An ACEI should be 
used first-line where there is evidence of 
nephropathy.10
Patient	perspective	
Decision on treatment goals should be 
reached in full discussion with patients, 
since the trial evidence does not support 
one target BP. The aim should be to achieve 
as great a reduction in BP toward the target 
as is acceptable to the patient.
Patients have reservations about 
taking their antihypertensive medication 
(e.g. preference for non-drug measures 
to lower BP, anxiety about potential 
side effects of treatment, doubt whether 
treatment continues to be necessary).12 
NICE guidelines recommend that all patients 
should have an annual review of care to 
monitor BP, provide support, and discuss 
lifestyle, symptoms and medication.1
It is estimated that 0–80% of patients 
with hypertension do not take all of their 
prescribed medication.9 Reasons include 
the asymptomatic nature of hypertension, 
the need for long-term treatment, complex 
drug regimens, poor instructions, and 
disagreement about the need for treatment.9 
Non-adherence to medication should be 
considered when evaluating a patient with 
poor BP control.13 Understanding a patient’s 
reasons for not taking their medication 
is important for implementing effective 
strategies to improve the management of 
their hypertension.9
Conclusion
Managing hypertension is a challenge 
for both health professional and the patient. 
Updated guidelines should be utilised 
so as to provide optimal treatment and 
improve patient outcomes. Full involvement 
of patients in treatment decisions and 
regular review are essential for effective 
management.
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•	 Hypertension is a major modifiable risk factor for cardiovascular disease.
•	 The co-existence of other modifiable risk factors has a bearing on the management 
strategy for the patient (CVD risk assessment).
•	 Drug therapy should be offered to patients with persistently high BP of 
160/100mmHg or more, and patients at raised CVD risk (10-year risk of CVD of 
20% or more, or existing CVD or target organ damage) with persistent BP of 
>10/90mmHg.
•	 BBs are no longer considered by NICE as an appropriate choice for initial treatment 
of hypertension unless there are compelling reasons to use them (e.g. coronary 
artery disease).
•	 Patients should be involved in treatment decisions on an on-going basis.
Practice	Points
